{"id":4455,"date":"2025-09-09T13:40:50","date_gmt":"2025-09-09T10:40:50","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=4455"},"modified":"2025-09-09T13:43:30","modified_gmt":"2025-09-09T10:43:30","slug":"solid-biosciences-sgt-003-gene-therapy-phase-3-clinical-trial-nct07160634","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/tr\/solid-biosciences-sgt-003-gene-therapy-phase-3-clinical-trial-nct07160634\/","title":{"rendered":"Solid Biosciences, Hareket Halindeki Erkeklerde SGT-003 Gen Terapisinin (IMPACT DUCHENNE) 3. Faz Klinik \u00c7al\u0131\u015fmas\u0131n\u0131 Ba\u015flatt\u0131"},"content":{"rendered":"<p class=\"wp-block-paragraph\"><strong>Solid Biosciences taraf\u0131ndan geli\u015ftirilen SGT-003 gen terapisinin 3. faz \u00e7al\u0131\u015fmas\u0131n\u0131n (NCT07160634) Ekim 2025&#039;te ba\u015flay\u0131p Ocak 2029&#039;da tamamlanmas\u0131 bekleniyor.<\/strong> SGT-003 Faz 3 \u00e7al\u0131\u015fmas\u0131na 80 ayakta tedavi g\u00f6ren erkek kat\u0131lacak olup, \u00e7al\u0131\u015fma lokasyonlar\u0131 hen\u00fcz payla\u015f\u0131lmam\u0131\u015ft\u0131r. <strong>Devam\u0131n\u0131 oku<\/strong>: <a href=\"https:\/\/dmdwarrior.com\/tr\/faq-solid-biosciences-sgt-003-gene-therapy\/\" target=\"_blank\" rel=\"noreferrer noopener\">Solid Biosciences SGT-003 Gen Terapisi Hakk\u0131nda S\u0131k\u00e7a Sorulan Sorular<\/a><\/p>\n\n\n\n<h2 class=\"wp-block-heading\">SGT-003 Gen Terapisi Faz 3 \u00c7al\u0131\u015fmas\u0131 \u2013 NCT07160634 \u2013<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Bu, DMD&#039;li pediatrik ayakta tedavi g\u00f6ren erkek kat\u0131l\u0131mc\u0131larda SGT-003&#039;\u00fcn tek bir IV inf\u00fczyonunun etkinli\u011fini de\u011ferlendirmeyi ama\u00e7layan, Faz 3, \u00e7ift k\u00f6r, plasebo kontroll\u00fc bir \u00e7al\u0131\u015fmad\u0131r. \u0130kincil hedefler aras\u0131nda ek etkinlik ve g\u00fcvenlik sonu\u00e7lar\u0131n\u0131n de\u011ferlendirilmesi yer almaktad\u0131r.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>\u00c7al\u0131\u015fma Ba\u015flang\u0131c\u0131 (Tahmini)<\/strong>: 2025-10<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Birincil Tamamlanma (Tahmini)<\/strong>: 2029-01<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>\u00c7al\u0131\u015fman\u0131n Tamamlanmas\u0131 (Tahmini)<\/strong>: 2034-01<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Kat\u0131l\u0131mc\u0131 Say\u0131s\u0131 (Tahmini)<\/strong>: 80<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>\u00c7al\u0131\u015fma T\u00fcr\u00fc<\/strong>: M\u00fcdahaleci<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Konumlar<\/strong>: Hen\u00fcz konum verisi yok.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>\u00c7al\u0131\u015fmaya Uygun Ya\u015flar<\/strong>: 7 Ya\u015f - 11 Ya\u015f (Y\u00fcr\u00fcyebilen Erkekler)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Temel dahil etme ve hari\u00e7 tutma kriterleri. \u2013 <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT07160634\" target=\"_blank\" rel=\"noreferrer noopener\">NCT07160634<\/a> \u2013<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">SGT-003 Klinik Ara\u015ft\u0131rmas\u0131na Nas\u0131l Kat\u0131l\u0131rs\u0131n\u0131z?<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">SGT-003 faz 3 klinik \u00e7al\u0131\u015fmas\u0131na kat\u0131lmak i\u00e7in a\u015fa\u011f\u0131daki ileti\u015fim bilgilerini kullanabilirsiniz.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>\u0130sim<\/strong>: Solid Biosciences<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Telefon Numaras\u0131<\/strong>: 6173374680<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>E-posta<\/strong>: clinicaltrials@solidbio.com<\/p>","protected":false},"excerpt":{"rendered":"<p>The phase 3 study (NCT07160634) of the SGT-003 gene therapy developed by Solid Biosciences is expected to begin in October 2025 and be completed in January 2029. The SGT-003 Phase 3 study will include 80 ambulant males, moreover the study locations have not yet been shared. Read More: Frequently Asked Questions About Solid Biosciences SGT-003 [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":4459,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[27],"tags":[137,242,61,419,110,170,109],"class_list":["post-4455","post","type-post","status-publish","format-standard","has-post-thumbnail","category-research","tag-clinical-trial","tag-clinical-trials","tag-gene-therapy","tag-impact-duchenne","tag-sgt-003","tag-sgt-003-gene-therapy","tag-solid-biosciences"],"_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/4455","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/comments?post=4455"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/4455\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/media\/4459"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/media?parent=4455"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/categories?post=4455"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/tags?post=4455"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}